Arch Therapeutics, Inc. ARTH
We take great care to ensure that the data presented and summarized in this overview for Arch Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ARTH
Top Purchases
Top Sells
About ARTH
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
Insider Transactions at ARTH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 31
2023
|
Laurence Hicks Director |
BUY
Open market or private purchase
|
Indirect |
10,292
+50.0%
|
$0
$0.28 P/Share
|
|
Aug 31
2023
|
Terrence W Norchi PRESIDENT AND CHIEF EXECUTIVE |
BUY
Open market or private purchase
|
Direct |
6,862
+50.0%
|
$0
$0.28 P/Share
|
|
Aug 31
2023
|
Michael S Abrams CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
10,292
+50.0%
|
$0
$0.28 P/Share
|
|
Jul 06
2022
|
Terrence W Norchi PRESIDENT AND CHIEF EXECUTIVE |
BUY
Grant, award, or other acquisition
|
Direct |
72,435
+2.37%
|
-
|
|
Jul 06
2022
|
Laurence Hicks Director |
BUY
Grant, award, or other acquisition
|
Indirect |
108,652
+50.0%
|
-
|
|
Jul 06
2022
|
Michael S Abrams CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
108,652
+50.0%
|
-
|
|
Jul 30
2021
|
Dan Yrigoyen VICE PRESIDENT, SALES |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+50.0%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 27.4K shares |
|---|